Invention Grant
- Patent Title: Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
-
Application No.: US14510603Application Date: 2014-10-09
-
Publication No.: US09598355B2Publication Date: 2017-03-21
- Inventor: Robert Eugene Hormann , Bing Li
- Applicant: Intrexon Corporation
- Applicant Address: US VA Blacksburg
- Assignee: Intrexon Corporation
- Current Assignee: Intrexon Corporation
- Current Assignee Address: US VA Blacksburg
- Agency: Sterne, Kessler, Goldstein & Fox P.L.L.C.
- Main IPC: C07C241/04
- IPC: C07C241/04 ; C07C243/38 ; C07C281/02 ; C12N15/82 ; A01N37/18 ; A01N43/08 ; A01N43/10 ; A01N43/30 ; A01N43/32 ; A01N43/40 ; C07C269/06 ; C07C271/08 ; C07D213/82 ; C07D307/68 ; C07D317/68 ; C07D319/18 ; C07D333/38 ; A61K48/00

Abstract:
The present invention provides diacylhydrazine ligands and chiral diacylhydrazine ligands for use with ecdysone receptor-based inducible gene expression systems. Thus, the present invention is useful for applications such as gene therapy, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable. An advantage of the present invention is that it provides a means to regulate gene expression and to tailor expression levels to suit the user's requirements.
Public/Granted literature
Information query